Interviews

Part 2: Nancy Globus on Whether or Not Biosimilar Naming Causes Confusion

August 13th 2020

Nancy J. Globus, PharmD, vice president of Regulatory Affairs at the Accreditation Council for Medical Affairs (ACMA), discusses the truth behind 4-letter suffixes and product confusion among physicians and pharmacists.

Part 1: Nancy Globus, PharmD, Talks About the Purpose of Biosimilar Naming

August 11th 2020

Video

Nancy J. Globus, PharmD, vice president of Regulatory Affairs at the Accreditation Council for Medical Affairs (ACMA), discusses the history and controversy behind 4-letter suffixes used for biosimilars.

Part 2: Axinn Patent Attorneys Discuss New Challenges for Insulins Under the BPCIA

July 23rd 2020

Video

Ted Mathias and Stacie Ropka, PhD, intellectual property law partners with Axinn, Veltrop and Harkrider LLP, discuss patent disputes and interchangeability designations with regard to insulin products under the Biologics Price Competition and Innovation Act (BPCIA). This is Part 2 of the interview. To watch Part 1, click here.

Webinar: How Biosimilar Rebates Shape Payer Policies, Provider Behavior

July 22nd 2020

Video

A panel of experts discusses the ways in which payers restrict prescribing choices for physicians and what that means for the future of biosimilar utilization.

Rathore Discusses Study on Biosimilar Application Failures

July 22nd 2020

Video

The Center for Biosimilars® interviewed Anurag S. Rathore, PhD, whose team of investigators evaluated why applications for biosimilar approvals do not succeed. Large companies as well as small find the approval process challenging, but there is a learning curve that may be followed by more consistent approvals, he explains.

Part 1: Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman

July 21st 2020

Video

Ted Mathias and Stacie Ropka, PhD, intellectual property law partners with Axinn Veltrop and Harkrider LLP, met with The Center for Biosimilars® to discuss how insulins will be regulated under the Biologics Price Competition and Innovation Act (BPCIA) versus the Hatch-Waxman Act, as well as the new challenges follow-on manufacturers will face.

Part 2: Celltrion Marketing Head Discusses Company's Future

July 16th 2020

Video

Byoungseo Choi, head of marketing for Celltrion Healthcare, discusses Celltrion’s biosimilar pipeline, the competitive landscape for its products, and its plans to build a biosimilar production center in Wuhan, China.

Celltrion: Infliximab Biosimilar Shows Promise for COVID-19

July 14th 2020

Video

Byoungseo Choi, head of marketing for Celltrion Healthcare, discusses how Celltrion's infliximab biosimilar can aid in the treatment of coronavirus disease 2019 (COVID-19)–related inflammation, as well as the company’s launch plans for biosimilars through 2030.

Kathy Oubre: Other Players Complicate Biosimilar Use for Cancer Centers

July 2nd 2020

Video

Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center in Louisiana, president of the Louisiana Medical Group Management Association and member of the board of directors for the Community Oncology Alliance, discusses how payers, pharmacy benefit managers, and manufacturers make providing biosimilars complicated for patients and providers.

Ryan Haumschild, PharmD, Outlines Ways to Boost Physician Confidence in Biosimilars

July 1st 2020

Video

Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare in Atlanta, Georgia, discussed results to the survey he conducted on biosimilar utilization and planned initiatives about how to increase physician confidence in biosimilars.